Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice

Experimental Neurology

Volumn 261, Issue , 2014, Pages 620-632

  Cristofanilli, Massimiliano ^a   Rosenthal, Hannah ^a   Cymring, Barbara ^a   Gratch, Daniel ^a   Pagano, Benjamin ^a   Xie, Boxun ^a   Sadiq, Saud A ^a  

^a Uro Center of New York   (United States)

Author keywords

Cerebrospinal fluid; Demyelination lesion pathology; Inflammatory cytokines; Intracerebroventricular injection; Progressive multiple sclerosis

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; B LYMPHOCYTE; CELL ACTIVITY; CELL INFILTRATION; CELL LOSS; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DEMYELINATION; DISEASE COURSE; GENE EXPRESSION; GLIA CELL; HUMAN; MALE; MOLECULAR PATHOLOGY; MOUSE; MULTIPLE SCLEROSIS; MYELITIS; NERVE FIBER DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ROTAROD TEST; SCAR FORMATION; T LYMPHOCYTE; TH1 CELL; TH17 CELL; ANIMAL; C57BL MOUSE; CHEMISTRY; DEMYELINATING AUTOIMMUNE DISEASES, CNS; DISEASE MODEL; DRUG EFFECTS; FEMALE; GLIOSIS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MOTOR ACTIVITY; PATHOLOGY; PHYSIOLOGY; SPINAL CORD; TIME; ANIMAL CELL; AXONAL INJURY; BRAIN DAMAGE; BRAIN REGION; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID ANALYSIS; LYMPH NODE; LYMPHOCYTIC INFILTRATION; MACROPHAGE; NERVE DEGENERATION;

ADULT; ANIMALS; B-LYMPHOCYTES; CEREBROSPINAL FLUID; CYTOKINES; DEMYELINATING AUTOIMMUNE DISEASES, CNS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GLIOSIS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; MOTOR ACTIVITY; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; SPINAL CORD; TH17 CELLS; TIME FACTORS;

EID: 84906728635     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2014.07.020     Document Type: Article

References (40)

1. Awad A., Hemmer B., Hartung H.P., Kieseier B., Bennett J.L., Stuve O. Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J. Neuroimmunol. 2010, 219:1-7.
2. Barkhof F., Calabresi P.A., Miller D.H., Reingold S.C. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat. Rev. Neurol. 2009, 5:256-266.
3. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
4. Cristofanilli M., Cymring B., Lu A., Rosenthal H., Sadiq S.A. Cerebrospinal fluid derived from progressive multiple sclerosis patients promotes neuronal and oligodendroglial differentiation of human neural precursor cells in vitro. Neuroscience 2013, 250C:614-621.
5. Edwards K.R., Goyal J., Plavina T., Czerkowicz J., Goelz S., Ranger A., Cadavid D., Browning J.L. Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis. PLoS One 2013, 8:e81007.
6. Ferguson B., Matyszak M.K., Esiri M.M., Perry V.H. Axonal damage in acute multiple sclerosis lesions. Brain 1997, 120(Pt 3):393-399.
7. Franklin R.J. Why does remyelination fail in multiple sclerosis?. Nat. Rev. Neurosci. 2002, 3:705-714.
8. Fujimura H., Nakatsuji Y., Sakoda S., Toyooka K., Okuda Y., Yoshikawa H., Kaido M., Saeki Y., Mima T., Kishimoto T., Yanagihara T. Demyelination in severe combined immunodeficient mice by intracisternal injection of cerebrospinal fluid cells from patients with multiple sclerosis: neuropathological investigation. Acta Neuropathol. 1997, 93:567-578.
9. Gironi M., Bergami A., Brambilla E., Ruffini F., Furlan R., Comi G., Martino G. Immunological markers in multiple sclerosis. Neurol Sci 2000, 21:S871-875.
10. Gold R., Linington C., Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129:1953-1971.
11. Hafler D.A. Multiple sclerosis. J. Clin. Invest. 2004, 113:788-794.
12. Han M.H., Hwang S.I., Roy D.B., Lundgren D.H., Price J.V., Ousman S.S., Fernald G.H., Gerlitz B., Robinson W.H., Baranzini S.E., Grinnell B.W., Raine C.S., Sobel R.A., Han D.K., Steinman L. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008, 451:1076-1081.
13. Hao Q., Saida T., Nishimura M., Ozawa K., Saida K. Failure to transfer multiple sclerosis into severe combined immunodeficiency mice by mononuclear cells from CSF of patients. Neurology 1994, 44:163-165.
14. Harris V.K., Donelan N., Yan Q.J., Clark K., Touray A., Rammal M., Sadiq S.A. Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis. Mult. Scler. 2013, 19(11):1462-1472. 10.1177/1352458513477923.
15. Hauser S.L., Chan J.R., Oksenberg J.R. Multiple sclerosis: prospects and promise. Ann. Neurol. 2013, 74(3):317-327. (Review). 10.1002/ana.24009.
16. Hawker K., O'Connor P., Freedman M.S., Calabresi P.A., Antel J., Simon J., Hauser S., Waubant E., Vollmer T., Panitch H., Zhang J., Chin P., Smith C.H. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 2009, 66:460-471.
17. Ishizu T., Osoegawa M., Mei F.J., Kikuchi H., Tanaka M., Takakura Y., Minohara M., Murai H., Mihara F., Taniwaki T., Kira J. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005, 128:988-1002.
18. Jones R.E., Chou Y., Young A., Mass M., Vandenbark A., Offner H., Bourdette D. T cells with encephalitogenic potential from multiple sclerosis patients and Lewis rats fail to induce disease in SCID mice following intracisternal injection. J. Neuroimmunol. 1995, 56:119-126.
19. Kalinski P., Vieira P.L., Schuitemaker J.H., de Jong E.C., Kapsenberg M.L. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 2001, 97:3466-3469.
20. Kato K., Shimozato O., Hoshi K., Wakimoto H., Hamada H., Yagita H., Okumura K. Local production of the p40 subunit of interleukin 12 suppresses T-helper 1-mediated immune responses and prevents allogeneic myoblast rejection. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:9085-9089.
21. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., Giuliani F., Arbour N., Becher B., Prat A. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 2007, 13:1173-1175.
22. Kornek B., Storch M.K., Weissert R., Wallstroem E., Stefferl A., Olsson T., Linington C., Schmidbauer M., Lassmann H. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol. 2000, 157:267-276.
23. Lovas G., Szilagyi N., Majtenyi K., Palkovits M., Komoly S. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 2000, 123(Pt 2):308-317.
24. Matsushita T., Tateishi T., Isobe N., Yonekawa T., Yamasaki R., Matsuse D., Murai H., Kira J. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One 2013, 8:e61835.
25. Matusevicius D., Kivisakk P., He B., Kostulas N., Ozenci V., Fredrikson S., Link H. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult. Scler. 1999, 5:101-104.
26. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50:121-127.
27. Miller D.H., Leary S.M. Primary-progressive multiple sclerosis. Lancet Neurol. 2007, 6:903-912.
28. Navikas V., Matusevicius D., Soderstrom M., Fredrikson S., Kivisakk P., Ljungdahl A., Hojeberg B., Link H. Increased interleukin-6 mRNA expression in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis. J. Neuroimmunol. 1996, 64:63-69.
29. Nylander A., Hafler D.A. Multiple sclerosis. J. Clin. Invest. 2012, 122:1180-1188.
30. Rothe H., O'Hara R.M., Martin S., Kolb H. Suppression of cyclophosphamide induced diabetes development and pancreatic Th1 reactivity in NOD mice treated with the interleukin (IL)-12 antagonist IL-12(p40)2. Diabetologia 1997, 40:641-646.
31. Rovaris M., Confavreux C., Furlan R., Kappos L., Comi G., Filippi M. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol. 2006, 5:343-354.
32. Sadiq S. Multiple sclerosis. Merritt's Textbook of Neurology 2005, 134:941-962. 11th edition. L.P. Rowland (Ed.).
33. Saeki Y., Mima T., Sakoda S., Fujimura H., Arita N., Nomura T., Kishimoto T. Transfer of multiple sclerosis into severe combined immunodeficiency mice by mononuclear cells from cerebrospinal fluid of the patients. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:6157-6161.
34. Sakoda S., Nakatsuji Y., Fujimura H. Transfer of multiple sclerosis into SCID mice. Nihon Rinsho 1994, 52:2946-2951.
35. Simpson J.E., Newcombe J., Cuzner M.L., Woodroofe M.N. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J. Neuroimmunol. 1998, 84:238-249.
36. Smith M.E., Sommer M.A. Association between cell-mediated demyelination and astrocyte stimulation. Prog. Brain Res. 1992, 94:411-422.
37. Stangel M., Fredrikson S., Meinl E., Petzold A., Stuve O., Tumani H. The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat. Rev. Neurol. 2013, 9:267-276.
38. Stelmasiak Z., Koziol-Montewka M., Dobosz B., Rejdak K., Bartosik-Psujek H., Mitosek-Szewczyk K., Belniak-Legiec E. Interleukin-6 concentration in serum and cerebrospinal fluid in multiple sclerosis patients. Med. Sci. Monit. 2000, 6:1104-1108.
39. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., Bo L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338:278-285.
40. Williams A., Piaton G., Lubetzki C. Astrocytes-friends or foes in multiple sclerosis?. Glia 2007, 55:1300-1312.